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###### Incidence of IOC, POC, and overall complications for respective groups

  ----------------------------------------------------------------------------------------------------------------------------------
                     Study population *N* = 423   Two 3CO\   One 3CO\    ThO\       LSO\        Low-vol. sites\   High-vol. sites\
                                                  *n* = 32   *n* = 391   *n* = 72   *n* = 319   *n* = 96          *n* = 320
  ------------------ ---------------------------- ---------- ----------- ---------- ----------- ----------------- ------------------
  IOC, %             28                           38         28          30         28          46                23

  POC, %             45                           69         43          66         39          36                47

  Overall comp., %   58                           75         57          76         53          64                56
  ----------------------------------------------------------------------------------------------------------------------------------

Abbreviations: comp., complications; IOC, intraoperative complication; POC, postoperative complication; ThO, thoracic osteotomy; 3CO, three-column resection osteotomies.
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